|June 5, 2014|
|08:36 EDT||PTCT||PTC Therapeutics named a new top pick at Credit Suisse|
Credit Suisse said PTC Therapeutics is a new top pick following the recent CHMP recommendation. The firm expects PTC to launch Translarna in the EU in 2H and and views it as a potential billion-dollar drug. Shares are Outperform rated with a $40 price target.
News For PTCT From The Last 14 Days
Check below for free stories on PTCT the last two weeks.
|August 18, 2014|
|08:52 EDT||PTCT||PTC Therapeutics price target raised to $43 from $34 at Roth Capital|
Subscribe for More Information
|August 12, 2014|
|09:57 EDT||PTCT||PTC Therapeutics management to meet with Oppenheimer|
Meeting to be held in Toronto on August 18 hosted by Oppenheimer.
|August 11, 2014|
|15:27 EDT||PTCT||Wedbush to hold a conference|
Life Sciences Management Conference to be held in New York on August 12-13.
|August 7, 2014|
|14:05 EDT||PTCT||PTC Therapeutics reports publication of preclinical study results in SMA models|
PTC Therapeutics (PTCT) announced that he journal Science published results of a preclinical study demonstrating that treatment with orally available RNA splicing modifiers of the SMN2 gene starting early after birth is preventing deficits in mouse models of Spinal Muscular Atrophy or SMA. Stuart Peltz, CEO of PTC Therapeutics, said, "Using the experience and expertise in RNA biology we have gained at PTC over the last 16 years, we used our alternative splicing technology to identify and subsequently optimize investigational compounds that target the SMN2 splicing to produce the SMN protein. Our unique partnership with Roche and the SMA Foundation has allowed this project to rapidly move into clinical development." Luca Santarelli, Head of Neuroscience, Ophthalmology and Rare Diseases at Roche (RHHBY), said, "Although still preclinical, these results demonstrate how SMN2 splicing modifiers could correct the molecular deficit that causes SMA. This study represents an important step towards developing a potential therapeutic option for this devastating and currently untreatable condition. Early clinical trials are currently underway to determine the safety and tolerability of this approach."
|07:41 EDT||PTCT||PTC Therapeutics reports Q2 EPS (86c), consensus (75c)|
Reports Q2 revenue $1.68M, consensus $1.71M.
|06:48 EDT||PTCT||PTC Therapeutics files automatic mixed securities shelf|